ATMP Quality Technical Agreement guidance

Earlier this year, WFC worked with The Cell and Gene Therapy Catapult and the Advanced Therapy Treatment Centres (ATTC) network to produce guidance to help standardise and simplify Quality Technical Agreements (QTAs) for advanced therapy medicinal product (ATMP) research. The development of the guidance involved consultations with a broad group of stakeholders from the NHS, Higher Education, and Industry.

The guidance has been published as part of the Quality assurance and risk management section of the ATTC’s comprehensive Advanced Therapies NHS Readiness Toolkit, which can be found here.